CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today presented data showing that IMO-4200, a dual agonist of Toll-like receptor (TLR) 7 and TLR8, in combination with approved cancer treatments, rituximab or bortezomib, significantly increased antitumor activity in several preclinical lymphoma models. The presentation, entitled “Antitumor Activity of an RNA-Based Agonist of TLR7 and 8 in Preclinical Models of Hematological Malignancies,” was made at the 52nd Annual Meeting of the American Society for Hematology in Orlando, Florida by Idera scientists. In conjunction with the data presentation, Idera announced the selection of this compound as its lead TLR7/TLR8 agonist drug candidate for the treatment of hematological malignancies.
